NCT01719783 is a Phase 1 clinical trial of LAIV H5N2 in Influenza, sponsored by PATH.

Who is sponsoring NCT01719783?

NCT01719783 is sponsored by PATH.

What drugs are being tested in NCT01719783?

Interventions in NCT01719783: LAIV H5N2, Placebo.

Is NCT01719783 still recruiting?

NCT01719783 is currently completed. Last updated 26 November 2018.

Are results published for NCT01719783?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2018-11-26 · How we verify

NCT01719783

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Reactogenicity, Safety and Immunogenicity of a Live Monovalent A/17/Turkey/Turkey/05/133 (H5N2) Influenza Vaccine

Completed Phase 1 Results posted Last updated 26 November 2018

What this trial tests

Phase 1 trial testing LAIV H5N2 in Influenza in 40 participants. Completed in 1 January 2013.

Timeline

1 September 2012

Primary endpoint
1 January 2013

1 January 2013

Quick facts

Lead sponsor	PATH
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	prevention
Enrollment	40
Start date	1 September 2012
Primary completion	1 January 2013
Estimated completion	1 January 2013
Sites	1 location across Russia

Drugs / interventions tested

LAIV H5N2 — full drug profile →
Placebo

Conditions studied

Influenza — all drugs for Influenza →

Sponsor

PATH — full company profile →

Who can join

Adults 18 to 49, any sex, with Influenza. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Adverse Events by Severity
Time frame: 6 days
Occurrence of participants with adverse events associated with intranasal administration, by worst grade of severity

Sponsor's own description

To evaluate the safety profile of two intranasal doses of LAIV A/17/turkey/Turkey/05/133 (H5N2) in healthy adults.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

Cross-Reactivity of SARS-CoV-2 Nucleocapsid-Binding Antibodies and Its Implication for COVID-19 Serology Tests.
Rak A, Donina S, Zabrodskaya Y, Rudenko L, et al · · 2022 · cited 27× · PMID 36146847 · DOI 10.3390/v14092041
Clinical testing of pre-pandemic live attenuated A/H5N2 influenza candidate vaccine in adult volunteers: results from a placebo-controlled, randomized double-blind phase I study.
Rudenko L, Kiseleva I, Stukova M, Erofeeva M, et al · · 2015 · cited 21× · PMID 26296497 · DOI 10.1016/j.vaccine.2015.08.019
A Phase 1 Randomized Placebo-Controlled Study to Assess the Safety, Immunogenicity and Genetic Stability of a New Potential Pandemic H7N9 Live Attenuated Influenza Vaccine in Healthy Adults.
Kiseleva I, Isakova-Sivak I, Stukova M, Erofeeva M, et al · · 2020 · cited 7× · PMID 32532097 · DOI 10.3390/vaccines8020296
Genetic stability of live attenuated vaccines against potentially pandemic influenza viruses.
Kiseleva I, Dubrovina I, Fedorova E, Larionova N, et al · · 2015 · cited 5× · PMID 26432909 · DOI 10.1016/j.vaccine.2015.09.050
A novel immunofluorescent test system for SARS-CoV-2 detection in infected cells.
Rak A, Matyushenko V, Prokopenko P, Kostromitina A, et al · · 2024 · cited 3× · PMID 38820303 · DOI 10.1371/journal.pone.0304534
RDE Treatment Prevents Non-Specific Detection of SARS-CoV-2- and Influenza-Specific IgG Antibodies in Heat-Inactivated Serum Samples.
Goshina A, Matyushenko V, Mezhenskaya D, Rak A, et al · · 2023 · PMID 37366655 · DOI 10.3390/antib12020039

Verify or expand the search:

Other recruiting trials for Influenza

Currently open trials in the same condition.

NCT07215858 — BPL-1357 Against H1N1 Influenza Virus Challenge · Phase 2 · recruiting
NCT07496450 — A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults · Phase 3 · recruiting
NCT07302256 — A Clinical Trial of Influenza Virus Split Vaccine for Individuals Aged 60 Years and Above · Phase 1 · recruiting
NCT07431840 — Immune Defense Protein Impact On Respiratory Immune Outcomes · NA · recruiting
NCT07485855 — Influenza Vaccination Strategy for Patients With Hematologic Malignancy · Phase 3 · recruiting

Other PATH trials

Trials by the same sponsor.

NCT06895486 — Study of Co-administered (Types 1 & 2) Novel Oral Poliomyelitis Vaccines Evaluation · Phase 2 · recruiting
NCT06129916 — Assessing the Acceptability, Feasibility, Effectiveness and Cost-effectiveness of LADB · not yet recruiting
NCT06879327 — Infant Malaria Vaccine Schedule Optimization · Phase 2 · recruiting
NCT06137664 — Study of Trivalent and Bivalent (Types 1 & 2) Novel Oral Poliomyelitis Vaccines · Phase 1, PHASE2 · recruiting
NCT05758506 — Developing a Screening Tool for Primary Immunodeficiency Disease (PID) in Pakistan · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01719783 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by PATH
Last refreshed: 26 November 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01719783.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing